Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

Carlyn Tan, David Nemirovsky, Andriy Derkach, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi A Shah, Dhwani Patel, Kylee H Maclachlan, Oscar B Lahoud, Gunjan L. Shah, Michael Scordo, David J. Chung, Heather Landau, Sergio A Giralt, Alexander M Lesokhin, Neha Korde, Saad Usmani

Blood (2022) 140 (Supplement 1): 1817–1819.

https://doi.org/10.1182/blood-2022-169161

Published: 2022

Journal Articles

Tracking the Earliest Genomic Events in Multiple Myeloma Life-History

Blood (2022) 140 (Supplement 1): 1553–1555.

https://doi.org/10.1182/blood-2022-164742

Published: 2022

Journal Articles

A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression

Blood (2022) 140 (Supplement 1): 5066–5069.

https://doi.org/10.1182/blood-2022-163281

Published: 2022

Journal Articles

Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study

Francesca Castro, Nathan W. Sweeney, Andriy Derkach, Kadiatou Traore, Aishwarya Anuraj, Laura Guttentag, Jenna Blaslov, Ana Sahagun, Jay Hydren, Cynthia Chmielewski, Terry Golombick, Justin R Cross, Jun J Mao, Marcel R M van den Brink, Saad Usmani, Jennifer M. Ahlstrom, Alexander M Lesokhin, Urvi A Shah

Blood (2022) 140 (Supplement 1): 13079–13081.

https://doi.org/10.1182/blood-2022-160241

Published: 2022

Journal Articles

Low Intake of Fruits and Vegetables and High Intake of Processed Meats and Juices Are Associated with Risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) Database

Janine M. Joseph, Li Tang, Jens Hillengass, Kirsten Moysich, Ola Landgren, Saad Usmani, Alexander M Lesokhin, Susan E McCann, Urvi A Shah

Blood (2022) 140 (Supplement 1): 12556–12558.

https://doi.org/10.1182/blood-2022-167423

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 10150–10153.

https://doi.org/10.1182/blood-2022-163335

Published: 2022

Journal Articles

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Amrita Y. Krishnan, Salomon Manier, Evangelos Terpos, Saad Usmani, Josephine Khan, Rachel Pearson, Suzette Girgis, Yue Guo, Dana McAleer, Yunsi Olyslager, Tobias Kampfenkel, Niels W.C.J. van de Donk

Blood (2022) 140 (Supplement 1): 10148–10149.

https://doi.org/10.1182/blood-2022-160173

Published: 2022

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Jr., Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees

Blood (2022) 140 (Supplement 1): 10154–10156.

https://doi.org/10.1182/blood-2022-162473

Published: 2022

Journal Articles

The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Benjamin Diamond, Alexandra M Poos, Bachisio Ziccheddu, Kylee H Maclachlan, Yanming Zhang, Saad Usmani, Eileen M Boyle, Faith E Davies, Gareth J. Morgan, Ola Landgren, Marc S Raab, Francesco Maura, Niels Weinhold

Blood (2022) 140 (Supplement 1): 7125–7126.

https://doi.org/10.1182/blood-2022-166531

Published: 2022

Journal Articles

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Blood (2022) 140 (Supplement 1): 1137–1139.

https://doi.org/10.1182/blood-2022-160308

Published: 2022

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience

Malin Hultcrantz, Andriy Derkach, Hani Hassoun, Neha Korde, Kylee H Maclachlan, Sham Mailankody, Dhwani Patel, Urvi A Shah, Carlyn Tan, Theresia Akhlaghi, Issam S. Hamadeh, David J. Chung, Oscar B Lahoud, Heather Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Alexander M Lesokhin, Saad Usmani

Blood (2022) 140 (Supplement 1): 7246–7248.

https://doi.org/10.1182/blood-2022-171077

Published: 2022

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea

Blood (2022) 140 (Supplement 1): 4454–4456.

https://doi.org/10.1182/blood-2022-164851

Published: 2022

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Srinivasa Reddy Sanikommu, Shebli Atrash, Myra Robinson, Nury M. Steuerwald, Kristen Cassetta, Hsih-Te Yang, Saad Usmani, Edward A. Copelan, Belinda R. Avalos, Lawrence J. Druhan

Blood (2022) 140 (Supplement 1): 11416–11417.

https://doi.org/10.1182/blood-2022-170887

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

NARROW

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

Tracking the Earliest Genomic Events in Multiple Myeloma Life-History

A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression

Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study

Low Intake of Fruits and Vegetables and High Intake of Processed Meats and Juices Are Associated with Risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) Database

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only